RT Journal Article
T1 Vaccinations and Immunization Status in Pediatric Inflammatory Bowel Disease: A Multicenter Study From the Pediatric IBD Porto Group of the ESPGHAN.
A1 Martinelli, Massimo
A1 Giugliano, Francesca Paola
A1 Strisciuglio, Caterina
A1 Urbonas, Vaidotas
A1 Serban, Daniela Elena
A1 Banaszkiewicz, Aleksandra
A1 Assa, Amit
A1 Hojsak, Iva
A1 Lerchova, Tereza
A1 Navas-López, Víctor Manuel
A1 Romano, Claudio
A1 Sladek, Małgorzata
A1 Veres, Gabor
A1 Aloi, Marina
A1 Kucinskiene, Ruta
A1 Miele, Erasmo
K1 inflammatory bowel disease
K1 pediatrics
K1 vaccinations
AB Vaccine-preventable diseases and opportunistic infections in pediatric inflammatory bowel disease (IBD) are increasingly recognized issues. The aims of this study were to evaluate vaccinations, immunization status, and consequent therapeutic management in children with IBD and to analyze the differences among patients diagnosed before (Group 1) and after June 2012 (Group 2). This was a multicenter, retrospective cohort investigation. Between July 2016 and July 2017, 430 children with IBD were enrolled in 13 centers. Diagnosis, therapeutic history, vaccinations, and immunization status screening at diagnosis and at immunosuppressant (IM)/biologic initiation and reasons for incomplete immunization were retrieved. Vaccination rates at diagnosis were unsatisfactory for measles, mumps, and rubella (89.3%), Haemophilus influenzae (81.9%), meningococcus C (23.5%), chickenpox (18.4%), pneumococcus (18.6%), papillomavirus (5.9%), and rotavirus (1.9%). Complete immunization was recorded in 38/430 (8.8%) children, but specific vaccines were recommended in 79/430 patients (18.6%), without differences between the 2 groups. At IM start, 22% of children were tested for Epstein-Barr virus (EBV) status, with 96.2% of EBV-naïve patients starting azathioprine, without differences between Groups 1 and 2. Screening for latent tuberculosis (TB) before start of biologics was performed in 175/190 (92.1%), with up to 9 different screening strategies and numerous inconsistencies. We demonstrated a poor immunization status at diagnosis in children with IBD, which was not followed by proper vaccination catch-up. EBV status before IM initiation and latent TB before biologics were not adequately assessed. Thus, the overall impact of the current guidelines seems unsatisfactory.
YR 2020
FD 2020
LK http://hdl.handle.net/10668/14635
UL http://hdl.handle.net/10668/14635
LA en
DS RISalud
RD Apr 7, 2025